WebIt is important to remind that gemcitabine-induced lung toxicity is a diagnosis of exclusion. Alternative conditions must be ruled out, including pneumonia, pulmonary embolus, cardiac-related respiratory distress, malignancy, lymphangitic carcinomatosis, and exacerbation of chronic lung conditions. WebOverall, gemcitabine is relatively well tolerated. How-ever, a few reports have described gemcitabine-induced lung toxicity [1–7]. Recently, this toxicity was reported in patients with ovarian cancer [2, 8, 9]. Although up to 23% of patients treated with gemcitabine may develop dyspnea, a small fraction of patients may develop severe dyspnea,
Gemcitabine Pulmonary Toxicity in Ovarian Cancer Emily Ko, …
WebGemzar Pharmacologic class: Antimetabolite (pyrimidine analog) Therapeutic class: Antineoplastic Pregnancy risk category D Action Kills malignant cells undergoing DNA … WebJun 23, 2014 · Gemcitabine is a nucleoside analog, which is a commonly used agent for various solid organ malignancies. Phase 1 and 2 trials with gemcitabine did not show significant risk for cardiotoxicity; however, with its widespread clinical use over the last decade, a few cases of cardiotoxicity related to gemcitabine use have been reported. coop grocery stores massachusetts
MATERIAL SAFETY DATA SHEET - Pfizer
WebCommon grade 3/4 non-hematologic toxicities were nausea/vomiting (22.0%), infection (12.3%), and febrile neutropenia (11.4%). Conclusion: Cisplatin and gemcitabine are feasible for use in the adjuvant setting with a favorable toxicity profile and superior tolerability compared with published data on cisplatin and vinorelbine. MeSH terms WebReproductive toxicity Specific target organ toxicity - single exposure Due to lack of data the classification is not possible. Specific target organ toxicity - repeated exposure Animal studies have reported the following effects: Blood effects (decreased red blood cell, white blood cell, and platelet counts). (Gemcitabine Hydrochloride) WebMar 28, 2024 · Difficult/late diagnosis as well as the poor efficacy and high toxicity of chemotherapeutic drugs result in dismal prognosis. With the aim of improving the treatment outcome of PDAC, we tested the effect of combining Gemcitabine with a novel single chain bispecific antibody (scDb) targeting the cancer-specific hERG1/β1 integrin complex. famous art museums in usa